Ensign Peak Advisors
TNGX icon

Ensign Peak Advisors’s Tango Therapeutics TNGX Stock Holding History

Ensign Peak Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-57,319
Closed -$177K – 1727
2024
Q4 		$177K Buy
57,319
+28,700
+100% +$133K ﹤0.01% 1698
2024
Q3 		$220K Sell
28,619
-243,203
-89% -$2.32M ﹤0.01% 1692
2024
Q2 		$2.33M Sell
271,822
-234,560
-46% -$1.81M ﹤0.01% 849
2024
Q1 		$4.02M Buy
506,382
+11,169
+2% +$120K 0.01% 692
2023
Q4 		$4.9M Hold
495,213
– – 0.01% 624
2023
Q3 		$5.58M Hold
495,213
– – 0.01% 538
2023
Q2 		$1.64M Hold
495,213
– – ﹤0.01% 952
2023
Q1 		$1.96M Hold
495,213
– – ﹤0.01% 864
2022
Q4 		$3.59M Buy
495,213
+107,260
+28% +$754K 0.01% 646
2022
Q3 		$1.4M Buy
387,953
+88,562
+30% +$378K ﹤0.01% 919
2022
Q2 		$1.36M Buy
299,391
+193,735
+183% +$1.17M ﹤0.01% 969
2022
Q1 		$801K Hold
105,656
– – ﹤0.01% 1324
2021
Q4 		$1.16M Buy
105,656
+52,156
+97% +$627K ﹤0.01% 1202
2021
Q3 		$692K Buy
+53,500
New +$641K ﹤0.01% 1550

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ensign Peak Advisors's TNGX Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Tango Therapeutics (TNGX) in Q1 2025, closing a stake of 57,319 shares — an estimated $177K sold.

Ensign Peak Advisors first reported a position in TNGX in Q3 2021 and held it in 14 quarters. The position peaked at $5.58M in Q3 2023. 122 funds tracked by Wall St. Rank hold TNGX as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Tango Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 57,319 Tango Therapeutics shares in Q1 2025, an estimated $177K.
  • Ensign Peak Advisors first reported a position in Tango Therapeutics in Q3 2021 and held it in 14 quarters.
  • Ensign Peak Advisors's Tango Therapeutics position peaked at $5.58M in Q3 2023.
  • 122 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.